98 related articles for article (PubMed ID: 34062616)
1. Receipt of guideline-concordant care among young adult women with breast cancer.
White DP; Kurian AW; Stevens JL; Liu B; Brest AE; Petkov VI
Cancer; 2021 Sep; 127(18):3325-3333. PubMed ID: 34062616
[TBL] [Abstract][Full Text] [Related]
2. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study.
LeMasters T; Madhavan SS; Sambamoorthi U; Hazard-Jenkins HW; Kelly KM; Long D
J Natl Compr Canc Netw; 2018 Jun; 16(6):703-710. PubMed ID: 29891521
[No Abstract] [Full Text] [Related]
4. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
[TBL] [Abstract][Full Text] [Related]
5. Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta.
Collin LJ; Yan M; Jiang R; Gogineni K; Subhedar P; Ward KC; Switchenko JM; Lipscomb J; Miller-Kleinhenz J; Torres MA; Lin J; McCullough LE
J Natl Compr Canc Netw; 2021 Aug; 19(11):1242-1251. PubMed ID: 34399407
[TBL] [Abstract][Full Text] [Related]
6. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
7. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
De Camargo Cancela M; Comber H; Sharp L
Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
[TBL] [Abstract][Full Text] [Related]
10. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
Vyas AM; Aroke H; Kogut S
J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
[TBL] [Abstract][Full Text] [Related]
11. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
[TBL] [Abstract][Full Text] [Related]
12. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
14. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
15. Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE; Owonikoko TK; Ramalingam SS; Curran WJ; Higgins KA
Clin Lung Cancer; 2017 Nov; 18(6):706-718. PubMed ID: 28601387
[TBL] [Abstract][Full Text] [Related]
16. HER2 status and disparities in luminal breast cancers.
Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
19. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Mortality in Older and Younger Patients in California.
Tao L; Schwab RB; San Miguel Y; Gomez SL; Canchola AJ; Gago-Dominguez M; Komenaka IK; Murphy JD; Molinolo AA; Martinez ME
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):303-310. PubMed ID: 30333222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
